ERAS

Erasca, Inc. - Common Stock (ERAS)

About Erasca, Inc. - Common Stock (ERAS)

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Details

Daily high

$15.18

Daily low

$13.17

Price at open

$14.91

52 Week High

$24.28

52 Week Low

$2.10

Market cap

5.2B

Dividend yield

Volume

5.4M

Avg. volume

4.9M

P/E ratio

-15.62

Erasca, Inc. - Common Stock News